However, PI3K/mTOR inhibition comes at a cost of adverse effects, including hyperglycemia, noninfectious pneumonitis and immunosuppression, which significantly limits the use of PI3K/mTOR inhibitors in cancer therapy7, 10, 11. This evidence concerns the gene MTOR and Hyperglycemia.